Newly synthesized rifamycin derivatives, KRM-1648, KRM-1657, KRM-1668, KRM-1686, and KRM-1687, having the chemical structures of 3'-hydroxy-5'-(4-alkylpiperazinyl)-benzoxazinorifamycins (alkyl residues: isobutyl, propyl, sec-butyl, sec-butyl [R configuration], and sec-butyl [S configuration], respectively), were studied for their in vitro antimycobacterial activities. Representative (KRM-1648) MICs for 90% of the strains tested, determined by the agar dilution method on 7H11 medium, of various pathogenic mycobacteria (9 species, 174 strains) were as follows (in micrograms per milliliter): Mycobacterium tuberculosis (rifampin [RMP]-susceptible strains), <0.0125; M. tuberculosis (RMP-resistant strains), 12.5; M. kansasii, 0.05; M. marinum, .0.0125; M. scrofulaceum, 0.1; M. avium, 1.56; M. intracellulare, 0.1; M. fortuitum, >100; and M. chelonae subsp. abscessus and M. chelonae subsp. chelonae, >100. These values are more than 64 times lower than those of RMP, except for the values against RMP-resistant M. tuberculosis (8 times lower) and those against rapid growers, including M. fortuitum and M. chelonae (the same as those of RMP). The other derivatives had similar levels of in vitro activity against these mycobacteria. When murine peritoneal macrophages in which M. intracellulare was phagocytosed in vitro were cultured in the presence of the benzoxazinorifamycins (1 ,ug/ml), much more rapid killing of the organisms ingested in the macrophages was seen compared with when the same amount of RMP was added to the medium. The addition of benzoxazinorifamycins at the concentration of 0.05 ,ig/ml caused more marked suppression of intracellular growth of the organisms compared with addition of RMP. KRM-1648 and KRM-1657 inhibited intracellular growth of M. tuberculosis, and their efficacies were much greater than that of RMP.
Rifampin (RMP), a rifamycin derivative, is highly active against a number of mycobacteria, especially slow growers such as Mycobacterium tuberculosis, M. kansasii, and M. marinum (3, 22, 23) , and is used for the treatment of patients with tuberculosis and some atypical mycobacterial infections (4, 8, 17, 21, 27) . However, certain disadvantages have recently arisen in the clinical use of RMP. First, there are increasing numbers of RMP-resistant strains in humanderived M. tuberculosis (26) . Second, RMP combination therapy exhibits relatively unsatisfactory efficacy against infections caused by M. avium complex (MAC) (4, 21, 27) because of its considerably weak in vitro activity against the MAC (3, 22, 23) , possibly because of the permeability barrier of the organisms (7, 20) . Although other types of rifamycin derivatives, e.g., rifabutin (RBT) (2) , rifapentine (1), FCE22807 (6) , CGP40/469A (6), CGP-7040 (10) , and P-DEA (10) , have been developed and although the drugs have higher in vitro antimycobacterial activities than RMP (2, 3, 5, 9, 23, 28) , the drugs are generally not so active against MAC infection in humans, particularly immunocompromised hosts (12, 14, 29) . Since MAC infections are increasing remarkably in immunocompromised hosts, particularly in AIDS patients (30) , the need to develop new antimicrobial agents including rifamycin derivatives which have a strong activity against the MAC is urgent. In this study, we described the in vitro activities of newly synthesized benzoxazinorifamycins against various pathogenic mycobacteria, especially the MAC. * M. chelonae subsp. chelonae) for 3 to 7 days with 0.1% Tween 80 in saline to give an optical density at 540 nm of 0.1 (approximately 107 CFU/ml) as measured by the Hitachi model 100-10 spectrophotometer (Hitachi Industry Co., Hitachi, Japan); the organisms were then diluted 10 times in the saline. Bacterial suspension (5 ,il) was spotted on 7H11 agar plates containing 100 -0.0125-,ug/ml doses (twofold dilution) of drugs. The MICs of the drugs were determined 7 days (rapid growers) or 1 ,ug of the drug per ml at 37°C for up to 5 days. At intervals, the macrophage monolayer culture was thoroughly rinsed with phosphate-buffered saline (PBS) to remove antimicrobial agents. Thereafter, two to three wells for each experimental group were stained with Giemsa solution to count the number of macrophages per well. The remaining macrophage monolayer cultures (three wells for each experimental group) were treated with distilled water to lyse macrophages, and the CFU of organisms in the macrophage lysate were counted on 7H11 agar plates (23) . Results were expressed as CFU/100 macrophages.
RESULTS
In vitro antimicrobial activity. Table 1 However, bacterial growth caused by the KRMs was slower than that in the drug-free medium compared with overall growth throughout the 5-day incubation, and KRM efficacies were also significantly higher than that of RMP. KRM-1648 and KRM-1657 seemed to exhibit higher efficacies of bacterial growth inhibition than RBT (although there was no statistical difference at P < 0.05), which has potent killing activity against M. intracellulare in resident or immunologically activated peritoneal and alveolar macrophages (16) . The activities of the other KRMs were equal to that of RMP. Table 3 compares activities of KRM-1648 and KRM-1657 against M. intracellulare ingested in macrophages, when added at concentrations of 0.05 and 0.5 jig/ml. It was again confirmed that KRM-1657 had somewhat higher antimicrobial activity than KRM-1648. (Table 4) , marked growth inhibition of the intracellular organisms was seen during the whole incubation time. KRM-1657 achieved bacterial killing from day 3 to 5. On the basis of weight, the activities of these benzoxazinorifamycins against intracellular M. tuberculosis were much more potent than that of RMP but nearly the same as that of RBT. However, it should be noted that this ordering for anti-M. tuberculosis activity cannot be directly applied to their in vivo activities, since concentrations of the KRMs in blood were markedly lower than that of RMP, although such an obvious difference was not observed for the concentrations in the lung. Table 1 .
DISCUSSION
This study elucidated that benzoxazinorifamycins, which are newly synthesized rifamycin derivatives, have remarkably excellent in vitro antimycobacterial activities, especially against pathogenic mycobacteria. Their MICs against slow growers were much lower than those of RMP. We previously found that RBT is 4 to 32 times more active than RMP, on the basis of MIC90s determined by the same method as performed in the present study (23) (Table 1) , except for MICs against M. fortuitum and M. chelonae, to which RBT exhibits considerably higher activity than did the KRMs. As mentioned above, concentrations in plasma of KRMs were markedly lower than that of RMP, although the concentrations in the lung were similar. Therefore, in vivo efficacies of the KRMs, especially against organisms in the bloodstream, seem not to be so remarkably improved compared with that of RMP. However, the KRMs may exhibit a superior in vivo activity against mycobacteria growing in the lungs, which is the target organ of MAC infection.
It is noteworthy that the benzoxazinorifamycins showed a high potency of activity selective against slowly growing mycobacteria. The MICs of benzoxazinorifamycins against rapidly growing mycobacteria were in the same level as that of RMP (Table 1 ). This may imply a possible diversity either in cellular mechanisms of initiation step of transcription (25) or in cell wall permeability for drugs (7) between slowly growing and rapidly growing mycobacteria. It is interesting to know the combined effect of the KRMs with other drugs, such as ethambutol, which gives synergistic in vitro activity with RBT (9 (10a) . In any case, the benzoxazinorifamycins seem promising for clinical use in the treatment of MAC infections. Our preliminary experiments showed that these drugs had lower toxicities in mice and rats than RMP. Successive oral administration of KRM-1648 or KRM-1657 at doses of 100 up to 600 mg/day/kg of body weight to mice for 5 days and to rats for 2 weeks did not cause any serious toxic symptoms (unpublished data), but a certain level of toxicity was noted for RPM at 600 mg/kg. We previously found that the therapeutic efficacy of RMP could be markedly increased by a drug delivery system in which liposome vesicles were used (24) . Therefore, therapeutic efficacies of the benzoxazinorifamycins may be much improved by using an appropriate delivery system. Further detailed studies concerning in vivo therapeutic activities of the drugs against various mycobacterial infections, in particular MAC infections, induced in mice are now under way.
